Institute for Wealth Management LLC. cut its holdings in shares of Eli Lilly And Co (NYSE:LLY) by 1.0% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 10,952 shares of the company’s stock after selling 115 shares during the quarter. Institute for Wealth Management LLC.’s holdings in Eli Lilly And Co were worth $1,213,000 at the end of the most recent quarter.
Several other hedge funds have also bought and sold shares of LLY. Jones Financial Companies Lllp increased its stake in shares of Eli Lilly And Co by 9.2% in the second quarter. Jones Financial Companies Lllp now owns 7,211 shares of the company’s stock worth $799,000 after buying an additional 606 shares during the period. Hillsdale Investment Management Inc. increased its stake in shares of Eli Lilly And Co by 1,071.1% in the second quarter. Hillsdale Investment Management Inc. now owns 4,450 shares of the company’s stock worth $494,000 after buying an additional 4,070 shares during the period. Clarius Group LLC increased its stake in shares of Eli Lilly And Co by 30.3% in the second quarter. Clarius Group LLC now owns 6,040 shares of the company’s stock worth $669,000 after buying an additional 1,404 shares during the period. Next Capital Management LLC increased its stake in shares of Eli Lilly And Co by 6.2% in the second quarter. Next Capital Management LLC now owns 2,195 shares of the company’s stock worth $243,000 after buying an additional 128 shares during the period. Finally, Wealth Enhancement Advisory Services LLC increased its stake in shares of Eli Lilly And Co by 128.8% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 29,178 shares of the company’s stock worth $3,172,000 after buying an additional 16,428 shares during the period. 79.48% of the stock is currently owned by hedge funds and other institutional investors.
In other Eli Lilly And Co news, CFO Joshua L. Smiley bought 426 shares of the company’s stock in a transaction dated Wednesday, June 5th. The shares were purchased at an average price of $118.03 per share, for a total transaction of $50,280.78. Following the acquisition, the chief financial officer now owns 30,410 shares in the company, valued at approximately $3,589,292.30. The purchase was disclosed in a filing with the SEC, which is available at this link. Also, VP Michael J. Harrington sold 16,000 shares of the business’s stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $116.72, for a total transaction of $1,867,520.00. Following the sale, the vice president now owns 110,300 shares in the company, valued at approximately $12,874,216. The disclosure for this sale can be found here. Insiders own 0.11% of the company’s stock.
NYSE:LLY traded up $0.29 during trading hours on Friday, hitting $110.52. The company had a trading volume of 3,423,700 shares, compared to its average volume of 4,237,085. The company has a market capitalization of $106.42 billion, a PE ratio of 19.91, a price-to-earnings-growth ratio of 1.95 and a beta of 0.19. The stock has a 50-day moving average price of $110.59 and a 200 day moving average price of $118.03. Eli Lilly And Co has a 52 week low of $103.65 and a 52 week high of $132.13. The company has a debt-to-equity ratio of 4.98, a current ratio of 1.13 and a quick ratio of 0.87.
Eli Lilly And Co (NYSE:LLY) last released its quarterly earnings results on Tuesday, July 30th. The company reported $1.50 earnings per share for the quarter, beating the consensus estimate of $1.45 by $0.05. The business had revenue of $5.64 billion for the quarter, compared to analysts’ expectations of $5.59 billion. Eli Lilly And Co had a net margin of 33.76% and a return on equity of 70.86%. The firm’s revenue for the quarter was up .9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.48 earnings per share. Analysts anticipate that Eli Lilly And Co will post 5.72 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Thursday, August 15th will be issued a $0.645 dividend. This represents a $2.58 annualized dividend and a yield of 2.33%. The ex-dividend date of this dividend is Wednesday, August 14th. Eli Lilly And Co’s dividend payout ratio (DPR) is currently 46.49%.
Eli Lilly And Co Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Featured Article: What is the Difference Between Common Shares and Convertible Shares?
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.